William A. Hartman, President & Chief Executive Officer of Premier Biomedical, Inc. (BIEI), Interviews with The Wall Street Transcript

Wall Street Transcript

67 WALL STREET, New York - April 26, 2013 - The Wall Street Transcript has just published its Biotechnology and Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Health Care - Biotechnology and Pharmaceuticals - Executive Officer Interviews - Biotechnology and Pharmaceutical Investing - Orphan Drug and Biologics Manufacturing - Biotechnology and Pharmaceutical Companies Valuation

Companies include: Premier Biomedical, Inc. (BIEI) and many more.

In the following excerpt from the Biotechnology and Pharmaceuticals Report, the President & Chief Executive Officer of Premier Biomedical, Inc. (BIEI) discusses company strategy and the outlook for this vital industry:

TWST: Please provide a short profile and overview of your company, Premier Biomedical.

Mr. Hartman: Premier Biomedical is a medical treatment research and development corporation. Our purpose is to discover and develop medical treatments for humans, with an initial focus on treatments for cancer and Alzheimer's disease. I co-founded the company with Dr. Mitchell Felder, who developed the Felder Doctrine, the scientific method we employ in our research and testing. With the Felder Doctrine, we physically remove the pathophysiologic basis of the disease.

We've very successfully leveraged our capabilities by partnering with the University of Texas at El Paso on joint research for cancer, Alzheimer's disease and traumatic brain injury. We've also established a cooperative research and development agreement, CRADA, with the Department of Defense and the U.S. Army through William Beaumont Army Medical Center, for which we're awaiting approval of protocols to proceed. With these key partnerships, we are successfully able to tap into enormous technology resources and leverage our capabilities without significant cost - a great advantage to us and to the development of our technology.

TWST: What is the science behind your sequential-dialysis technique? Would you explain for our readers how removing proteins that are responsible for pathological changes to the brain works?

Mr. Hartman: We process body fluids, such as blood for blood-borne diseases and cerebral spinal fluid for neurologic-based diseases. Most traditional medications and/or neurological procedures involve pills and/or blockers or inhibitors that go through the gastrointestinal system. As an analogy, this is akin to trying to eliminate a specific pest in a tributary or a stream by throwing chemicals into the Pacific Ocean. The problem is that the chemicals end up affecting the entire body of water...

For more of this interview and many others visit the Wall Street Transcript - a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs, portfolio managers and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

View Comments (0)